| UniProt/SwissProt ID: | TPIS_HUMAN |
| Description: | triosephosphate isomerase 1 [Source:HGNC Symbol;Acc:12009] |
| Location: | chr12 p13.31 |
| Node attribute: | gene |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| S260 | CKELAsQPDVD | TIM | PhosphoSitePlus |
| S235 | LKSNVsDAVAQ | TIM | PhosphoSitePlus |
| T28 | RLRADtDLQRL | PhosphoSitePlus | |
| Y105 | AAQNCyKVTNG | TIM | PhosphoSitePlus |
| S204 | DAVAQsTRIIY | HPRD | |
| Y16 | HFAALyISGQW | PhosphoSitePlus | |
| S58 | NGRKQsLGELI | TIM | PhosphoSitePlus |
| T251 | YGGSVtGATCK | TIM | PhosphoSitePlus |
| S249 | IIYGGsVTGAT | TIM | PhosphoSitePlus |
| S241 | DAVAQsTRIIY | TIM | PhosphoSitePlus |
| T108 | NCYKVtNGAFT | TIM | PhosphoSitePlus |
| S232 | RGWLKsNVSDA | TIM | PhosphoSitePlus |
| T28 | GELIGtLNAAK | HPRD | |
| S117 | FTGEIsPGMIK | TIM | PhosphoSitePlus |
| S21 | NGRKQsLGELI | HPRD; phosphoELM; SysPTM | |
| T65 | GELIGtLNAAK | TIM | PhosphoSitePlus |
| Y85 | APPTAyIDFAR | TIM | PhosphoSitePlus |
| S143 | HVFGEsDELIG | TIM | PhosphoSitePlus |
| S80 | FTGEIsPGMIK | HPRD; SysPTM | |
| T71 | NCYKVtNGAFT | HPRD | |
| Y246 | STRIIyGGSVT | TIM | PhosphoSitePlus |
| S198 | LKSNVsDAVAQ | HPRD | |
| Y202 | KVVLAyEPVWA | TIM | PhosphoSitePlus |
| S195 | RGWLKsNVSDA | HPRD | |
| Dephosphorylation site |
| TPIS_HUMAN do not have dephosphorylation site. |
| Mutation site |
| Ensembl ID | Variation | Source | Cancer name | Pubmed |
|---|---|---|---|---|
| ENSP00000379933 | V213L | COSMIC | Skin Cancer | 21984974 |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000379933 | Non-small cell lung carcinoma | Metastasis | cell line | Up | 17537172 | ENSP00000379933 | hepatitis C virus | Normal vs. Cancer | tissue | Down | 0.3 | 18715028 | ENSP00000379933 | Breast Cancer | Treatment (none vs. SEL1L treatment) | cell line | Down | 0.11 | 15880780 | ENSP00000379933 | Hepatocellular Carcinoma | Normal vs. Cancer | tissue | Down | 0.06 | 15759316 | ENSP00000379933 | Breast Cancer | Normal vs. Cancer | tissue | Up | 2 | 15767701 | ENSP00000379933 | Breast Cancer | Treatment (chemosensitive vs. adriamycin-resistant) | cell line | Up | 2.4 | 17487377 | ENSP00000379933 | hepatitis C virus | Normal vs. Cancer | tissue | Down | 16762624 | ENSP00000379933 | hepatitis C virus | Normal vs. Cancer | tissue | Up | 16762624 | ENSP00000379933 | Hepatocellular Carcinoma | Treatment (none vs. Suberonylanilide hydroxamic acid (SAHA) treatment) | tissue | Up | 17593366 | ENSP00000379933 | hepatitis B virus | Normal vs. Cancer | tissue | Down | 0.38 | 17671684 | ENSP00000379933 | Hepatocellular Carcinoma | Cancer vs. Cancer (HCC vs. HuCCA) | cell line | Up | 20069059 | ENSP00000379933 | Lung Cancer | Normal vs. Cancer | tissue | Up | 16342241 | ENSP00000379933 | Lung Cancer | Normal vs. Cancer | tissue | Up | 16342241 | ENSP00000379933 | Non-small cell lung carcinoma | Metastasis | cell line | Down | 0.31 | 17418446 | ENSP00000379933 | Lung Cancer | Treatment (none vs. Mitoxantrone resistance) | cell line | Down | 0.8 | 17593620 | ENSP00000379933 | Lung Cancer | Treatment (none vs transfected with pc3.1-hPNAS5) | cell line | Down | 19795389 | ENSP00000379933 | Non-small cell lung carcinoma | Treatment (none vs CIGB-300 treatment) | cell line | Down | 0.1 | 20804217 | ENSP00000379933 | Non-small cell lung carcinoma | Treatment (none vs CIGB-300 treatment) | cell line | Down | 0.34 | 20804217 | ENSP00000379933 | Gastric Cancer | Treatment (none vs. drug-resistant) | cell line | Down | 18309519 | ENSP00000379933 | Breast Cancer | Normal vs. Cancer | tissue | Up | 3.6 | 20005186 | ENSP00000379933 | Breast Cancer | Normal vs. Cancer | tissue | Up | >10 | 20005186 | ENSP00000379933 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1.5 | 20052998 | ENSP00000379933 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1.6 | 20052998 | ENSP00000379933 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.69 | 20052998 | ENSP00000379933 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.95 | 20052998 | ENSP00000379933 | Breast Cancer | Metastasis | cell line | Down | 0.46 | 20052998 | ENSP00000379933 | Breast Cancer | Metastasis | cell line | Down | 0.6 | 20052998 | ENSP00000379933 | Breast Cancer | Normal vs. Cancer | tissue | Up | 20560667 | ENSP00000379933 | chronic myeloid leukemia | Treatment (Imatinib-sensitive vs. Imatinib-resistant) | cell line | Up | 1.3 | 20417730 | ENSP00000379933 | Leukemia | Cancer vs. Cancer (subtype) | tissue | Up | 15501966 | ENSP00000379933 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | 14 | 17655343 | ENSP00000379933 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | 26 | 17655343 | ENSP00000379933 | Neoplasms by Histologic Type | Treatment (none vs. SB203580 treatment 3 hour) | cell line | Down | 0.3 | 15169874 | ENSP00000379933 | Renal Cancer | Normal vs. Cancer | tissue | Up | 1.7-4.4 | 12923786 | ENSP00000379933 | Renal Cancer | Normal vs. Cancer | tissue | Up | 2.7-6.1 | 12923786 | ENSP00000379933 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Up | 1.4 | 19714814 | ENSP00000379933 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Up | 2.5 | 19951750 | ENSP00000379933 | Biliary Tract Cancer | Metastasis | cell line | Up | 3.8 | 19299076 | ENSP00000379933 | Esophageal Cancer | Normal vs. Cancer | cell line | Down | 0.28 | 19090015 | ENSP00000379933 | Esophageal Cancer | Normal vs. Cancer | cell line | Down | 0.36 | 19090015 | ENSP00000379933 | Pancreatic Cancer | Normal vs. Cancer | tissue | Up | 3 | 19199705 |
| Hyperphosphorylation site |
| TPIS_HUMAN do not have hyperphosphorylation site. |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| SP1_HUMAN | TPIS_HUMAN | TF -> target gene | TRANSFAC |
| Function Annotation |
| KEGG Pathway |
| TPIS_HUMAN is not in KEGG pathway. |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:0006098 | pentose-phosphate shunt | IEA | biological_process |
| GO:0005975 | carbohydrate metabolic process | TAS | biological_process |
| GO:0044281 | small molecule metabolic process | TAS | biological_process |
| GO:0009790 | embryo development | IEA | biological_process |
| GO:0006096 | glycolysis | IEA | biological_process |
| GO:0016853 | isomerase activity | IEA | molecular_function |
| GO:0006094 | gluconeogenesis | IEA | biological_process |
| GO:0006006 | glucose metabolic process | TAS | biological_process |
| GO:0019682 | glyceraldehyde-3-phosphate metabolic process | IEA | biological_process |
| GO:0004807 | triose-phosphate isomerase activity | TAS | molecular_function |
| GO:0008152 | metabolic process | IEA | biological_process |
| GO:0005829 | cytosol | TAS | cellular_component |
| GO:0006006 | glucose metabolic process | IEA | biological_process |
| GO:0007275 | multicellular organismal development | IEA | biological_process |
| GO:0004807 | triose-phosphate isomerase activity | IEA | molecular_function |